Is conservative management of ductal carcinoma in situ risky?
Abstract Nonsurgical management of ductal carcinoma in situ is controversial and little is known about the long-term consequences of this approach. In this study, we aimed to determine the risk of (a) upstaging to invasive carcinoma at excision and (b) ipsilateral breast cancer events in patients wh...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-04-01
|
| Series: | npj Breast Cancer |
| Online Access: | https://doi.org/10.1038/s41523-022-00420-2 |
| _version_ | 1797425300097728512 |
|---|---|
| author | Lan Zheng Yesim Gökmen-Polar Sunil S. Badve |
| author_facet | Lan Zheng Yesim Gökmen-Polar Sunil S. Badve |
| author_sort | Lan Zheng |
| collection | DOAJ |
| description | Abstract Nonsurgical management of ductal carcinoma in situ is controversial and little is known about the long-term consequences of this approach. In this study, we aimed to determine the risk of (a) upstaging to invasive carcinoma at excision and (b) ipsilateral breast cancer events in patients who might have been eligible for nonsurgical management of DCIS trials. Data from women aged 20 years or older with a biopsy diagnosis of DCIS between January 1, 2010 to December 31, 2014 were collated. The women underwent biopsy and surgical resection (lumpectomy or mastectomy) and were treated with radiation or endocrine therapy as per treating physicians’ choice. The development of ipsilateral breast cancer events (IBEs) was analyzed in patients with at least 5 years of follow-up after standard of care therapy for DCIS. Subset-analysis was undertaken to identify the incidence of IBEs in patients eligible for nonsurgical management trials. The study population consisted of 378 patients with matched cases of biopsy and surgical excision. The overall upstaging rate to IBC was 14.3 and 12.9% for COMET, 8.8% for LORIS, and 10.7% for LORD trial “eligible” patients. At 5 years of follow-up, ~11.5% of overall and trial eligible patients developed IBEs of which approximately half were invasive IBEs. In conclusion, women with DCIS who would have been eligible for nonsurgical management trials have a significantly high risk of developing ipsilateral breast events within 5 years of diagnosis. Better selection criteria are needed to identify DCIS patients who are at very low risk for the development of IBC. |
| first_indexed | 2024-03-09T08:13:00Z |
| format | Article |
| id | doaj.art-e20faec312f94160a9470204af5f2ec5 |
| institution | Directory Open Access Journal |
| issn | 2374-4677 |
| language | English |
| last_indexed | 2024-03-09T08:13:00Z |
| publishDate | 2022-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Breast Cancer |
| spelling | doaj.art-e20faec312f94160a9470204af5f2ec52023-12-02T23:03:09ZengNature Portfolionpj Breast Cancer2374-46772022-04-01811610.1038/s41523-022-00420-2Is conservative management of ductal carcinoma in situ risky?Lan Zheng0Yesim Gökmen-Polar1Sunil S. Badve2Indiana University School of MedicineIndiana University School of MedicineIndiana University School of MedicineAbstract Nonsurgical management of ductal carcinoma in situ is controversial and little is known about the long-term consequences of this approach. In this study, we aimed to determine the risk of (a) upstaging to invasive carcinoma at excision and (b) ipsilateral breast cancer events in patients who might have been eligible for nonsurgical management of DCIS trials. Data from women aged 20 years or older with a biopsy diagnosis of DCIS between January 1, 2010 to December 31, 2014 were collated. The women underwent biopsy and surgical resection (lumpectomy or mastectomy) and were treated with radiation or endocrine therapy as per treating physicians’ choice. The development of ipsilateral breast cancer events (IBEs) was analyzed in patients with at least 5 years of follow-up after standard of care therapy for DCIS. Subset-analysis was undertaken to identify the incidence of IBEs in patients eligible for nonsurgical management trials. The study population consisted of 378 patients with matched cases of biopsy and surgical excision. The overall upstaging rate to IBC was 14.3 and 12.9% for COMET, 8.8% for LORIS, and 10.7% for LORD trial “eligible” patients. At 5 years of follow-up, ~11.5% of overall and trial eligible patients developed IBEs of which approximately half were invasive IBEs. In conclusion, women with DCIS who would have been eligible for nonsurgical management trials have a significantly high risk of developing ipsilateral breast events within 5 years of diagnosis. Better selection criteria are needed to identify DCIS patients who are at very low risk for the development of IBC.https://doi.org/10.1038/s41523-022-00420-2 |
| spellingShingle | Lan Zheng Yesim Gökmen-Polar Sunil S. Badve Is conservative management of ductal carcinoma in situ risky? npj Breast Cancer |
| title | Is conservative management of ductal carcinoma in situ risky? |
| title_full | Is conservative management of ductal carcinoma in situ risky? |
| title_fullStr | Is conservative management of ductal carcinoma in situ risky? |
| title_full_unstemmed | Is conservative management of ductal carcinoma in situ risky? |
| title_short | Is conservative management of ductal carcinoma in situ risky? |
| title_sort | is conservative management of ductal carcinoma in situ risky |
| url | https://doi.org/10.1038/s41523-022-00420-2 |
| work_keys_str_mv | AT lanzheng isconservativemanagementofductalcarcinomainsiturisky AT yesimgokmenpolar isconservativemanagementofductalcarcinomainsiturisky AT sunilsbadve isconservativemanagementofductalcarcinomainsiturisky |